H.C. Wainwright says SQZ Biotechnologies initial eAPC data raises more questions

After SQZ Biotechnologies presented clinical data from the enhanced Antigen Presenting Cell, or eAPC, and APC clinical trials at the ESMO-IO Congress, H.C. Wainwright analyst Emily Bodnar said that its "too early" to make any conclusions from initial eAPC data and that the APC combination data "do not look superior to monotherapy data." The analyst, who contends that the initial eAPC and APC combo data "raise more questions," keeps a Neutral rating on SQZ Biotechnologies shares.